Literature DB >> 21772114

[Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].

Shoko Akiyama1, Tomohito Niitani, Toshiaki Narasaka, Takashi Ohto, Makio Gamoh.   

Abstract

We present the case of a 76-year-old woman with a poorly-differentiated neuroendocrine carcinoma (PDNEC) of the ascending colon with liver metastases responding to calboplatin (CBDCA)/etoposide (ETP). She was admitted to our hospital with bloody stools, and was diagnosed with ascending colon cancer and multiple liver tumors. Total colonoscopy showed a Type 2 tumor in the ascending colon, and histological findings revealed adenocarcinoma from biopsy specimens. Right hemicolectomy with lymph nodes dissection was performed. Histologically, the tumor displayed PDNEC, the last feature identified by immunohistochemical markers for chromogranin and synaptophysin. After surgery, a combination of CBDCA and ETP was administered based on the chemotherapy for small-cell lung carcinoma in elderly, and there was a partial response and good control without emerging new lesions for more than two years.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772114

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Asymptomatic primary rectal neuroendocrine carcinoma presented as a large pelvic mass.

Authors:  Rapat Pittayanon; Linda Pantongrag-Brown; Naruemon Wisedopas; Rungsun Rerknimitr
Journal:  BMJ Case Rep       Date:  2014-02-03

Review 2.  Colorectal neuroendocrine carcinoma: A case report and review of the literature.

Authors:  Tomoaki Yoshida; Kenya Kamimura; Kazunori Hosaka; Koji Doumori; Hiromitsu Oka; Akito Sato; Yasuo Fukuhara; Shoji Watanabe; Tomomi Sato; Akira Yoshikawa; Takashi Tomidokoro; Shuji Terai
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.